Sapphiros is a Massachusetts-based private equity growth and expansion firm established in 2021. It focuses on investing in growth-stage companies that specialize in healthcare and diagnostic-related innovations. The firm aims to support the development of the next generation of diagnostics by bridging the gap between current practices and future technologies, emphasizing innovative, patient-centric diagnostic solutions.
BioCrucible is focused on advancing diagnostics through innovative technologies that leverage biomolecular condensate formation. The company is developing a highly sensitive and specific molecular diagnostic product aimed at addressing health challenges in underdeveloped countries, particularly for testing and treating infectious diseases. By utilizing a proprietary molecular technology platform, BioCrucible enhances the behavior and kinetics of engineered biological systems, enabling the creation of next-generation diagnostic tools that can improve health outcomes in resource-limited settings.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.